GLE/PIB is highly effective for clearing pediatric HCV

  • Jonas MM & al.
  • Hepatology
  • 29 Jun 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The pangenotypic combination of glecaprevir/pibrentasvir (GLE/PIB; Mavyret) is safe and effective for clearing HCV in adolescents ages 12-17 years.

Why this matters

Study design

  • Ongoing phase 2/3 DORA study (part 1) of once-daily GLE/PIB in 47 adolescent patients ages 12-17 (median, 14) years; 85% had acquired HCV perinatally.
  • The majority received an 8-week course (94%); 3 patients (6%) were treated for 16 weeks.
  • Funding: AbbVie.

Key results

  • Most patients were treatment-naive (77%) with genotype (GT) 1 infection (79%; 1a, 51%); GT2, GT3, and GT4 were also represented.
  • 23% had previously received peginterferon/ribavirin.
  • All 47 patients (100%; 95% CI, 92.4%-100.0%) achieved sustained virologic response at 12 weeks posttreatment.
  • There were no on-treatment virologic failures or relapses.
  • Pharmacokinetic exposure to GLE and PIB was comparable to that observed in adult steady-state exposure: 4380 vs 4800 and 1440 vs 1430 ng•h/mL.
  • Safety profile was consistent with that observed in adults, with no serious adverse events or adverse events leading to discontinuation.

Limitations

  • Open-label, nonrandomized design.
  • No patients with cirrhosis.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit